Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants
Rhea-AI Filing Summary
On August 3, 2026, Moleculin Biotech, Inc. Chief Financial Officer Jonathan P. Foster purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering at a combined price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly held 305,673 shares of common stock and 1,027,717 Series I Warrants to purchase common stock, which are reported with an expiration date of August 3, 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 293,333 shares
Net Buy
2 txns
Insider
Foster Jonathan P.
Role
Chief Financial Officer
Bought
1,173,332 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series I Warrants F1 | 879,999 | -- | -- |
| Purchase | Common Stock F1 | 293,333 | -- | -- |
Holdings After Transaction:
Series I Warrants — 1,027,717 shares (Direct);
Common Stock — 305,673 shares (Direct)
Footnotes (1)
- F1. On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Key Figures
Common shares purchased: 293,333 shares
Common shares held after: 305,673 shares
Series I Warrants purchased: 879,999 warrants
+4 more
7 metrics
Common shares purchased
293,333 shares
Shares of Moleculin Biotech common stock acquired by the CFO on August 3, 2026
Common shares held after
305,673 shares
Total direct common stock holdings of the CFO following the August 3, 2026 purchase
Series I Warrants purchased
879,999 warrants
Series I Warrants to purchase common stock acquired by the CFO in the same transaction
Series I Warrants held after
1,027,717 warrants
Total direct Series I Warrant holdings of the CFO after the August 3, 2026 acquisition
Combined purchase price
$0.75 per one share and three warrants
Pricing of units in the public offering purchased by the CFO
Warrant expiration date
August 3, 2031
Expiration date reported for the Series I Warrants acquired by the CFO
Total securities bought (shares + warrants)
1,173,332 securities
Sum of 293,333 common shares and 879,999 Series I Warrants acquired on August 3, 2026
Key Terms
Series I Warrants, public offering, combined purchase price, underlying security
4 terms
Series I Warrants financial
"acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares"
public offering financial
"three accompanying warrants in a public offering"
A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.
combined purchase price financial
"at a combined purchase price of $0.75 per one share of common stock"
underlying security financial
"underlying security title: Common Stock and underlying security shares reported"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Moleculin Biotech (MBRX) report for its CFO?
Moleculin Biotech’s CFO Jonathan P. Foster reported buying 293,333 common shares and 879,999 Series I Warrants on August 3, 2026. These were acquired in a public offering at a combined price of $0.75 per one share and three accompanying warrants.
How many Series I Warrants did the Moleculin Biotech (MBRX) CFO acquire and now hold?
The CFO acquired 879,999 Series I Warrants to purchase Moleculin Biotech common stock. Following this transaction, his total direct holdings of these warrants increased to 1,027,717, as reported in the insider trading disclosure for August 3, 2026.
What price did the Moleculin Biotech (MBRX) CFO pay for the stock and warrants?
He paid a combined purchase price of $0.75 per unit, where each unit consists of one share of common stock and three accompanying Series I Warrants. This combined pricing was part of Moleculin Biotech’s public offering on August 3, 2026.
When do the Moleculin Biotech (MBRX) Series I Warrants held by the CFO expire?
The reported Series I Warrants held by the CFO are shown with an expiration date of August 3, 2031. Each warrant is exercisable for Moleculin Biotech common stock, and the Form 4 links these terms to the August 3, 2026 acquisition.
Was the Moleculin Biotech (MBRX) CFO’s purchase made under a Rule 10b5-1 trading plan?
The disclosure indicates the Rule 10b5-1 checkbox is not affirmed for this transaction. The footnote instead describes the purchases as occurring in a public offering, without stating they were made under a pre-arranged trading plan.